concept

ACC

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about ACC: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

139Connections

23Hypotheses

0Analyses

50Outgoing

34Incoming

9Experiments

0Debates

No summary available yet. View on Wiki →

No AI portrait yet

💡 Concept Info

Name	ACC
Key Genes/Proteins	ABCA1, ACETYL-COA, ACLY, Albumin, AMPK, AND
Related Diseases	Als, ALS, Atherosclerosis, Autism, autism spectrum disorder

Wiki Pages (3)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    ACC["ACC"]
    ACC -->|"inhibits"| Als["Als"]
    ACC -->|"inhibits"| Ms["Ms"]
    ACC -->|"expressed in"| Atherosclerosis["Atherosclerosis"]
    ACC -->|"inhibits"| Tumor["Tumor"]
    ACC -->|"target for"| Fatty_Liver["Fatty Liver"]
    ACC -->|"inhibits"| ULK1["ULK1"]
    ACC -->|"activates"| AMPK["AMPK"]
    ACC -->|"inhibits"| Autophagy["Autophagy"]
    AMPK -->|"activates"| ACC
    KRAS["KRAS"] -->|"inhibits"| ACC
    ERK["ERK"] -->|"expressed in"| ACC
    CD36["CD36"] -->|"expressed in"| ACC
    FAS["FAS"] -->|"expressed in"| ACC
    SCD1["SCD1"] -->|"expressed in"| ACC
    SPR["SPR"] -->|"target for"| ACC
    LDL["LDL"] -->|"target for"| ACC

Outgoing (105)

Target	Relation	Type	Str
Polyunsaturated Fatty Acid Biosynthesis	regulates	pathway	0.85
Hepatic Lipogenesis	regulates	process	0.80
PV	regulates	gene	0.70
Als	associated_with	disease	0.65
Autism	associated_with	disease	0.65
Cancer	inhibits	disease	0.65
Ferroptosis	activates	disease	0.65
Tumor	activates	disease	0.65
Stroke	activates	disease	0.65
Inflammation	activates	disease	0.65
Metabolic Syndrome	activates	disease	0.65
Fatty Liver	therapeutic_target	disease	0.65
Neuroinflammation	activates	disease	0.65
ALS	activates	disease	0.65
Als	inhibits	disease	0.65
Atherosclerosis	expressed_in	disease	0.65
Ms	inhibits	disease	0.65
Als	therapeutic_target	disease	0.65
Tumor	therapeutic_target	disease	0.65
Carcinoma	associated_with	disease	0.65
Tumor	inhibits	disease	0.65
Cancer	associated_with	disease	0.65
Lung Cancer	associated_with	disease	0.65
IKK	inhibits	gene	0.60
BDNF	regulates	gene	0.60
synaptic plasticity	participates_in	pathway	0.60
BDNF	activates	gene	0.60
ACETYL-COA	therapeutic_target	gene	0.60
AMPK	associated_with	gene	0.60
ATP	associated_with	gene	0.60
AMPK	phosphorylates	gene	0.60
ATP	phosphorylates	gene	0.60
epigenetic regulation	participates_in	pathway	0.60
AUTOPHAGY	inhibits	gene	0.60
Oxidative Stress	activates	pathway	0.60
neurons	expressed_in	cell_type	0.60
AMPK	protects_against	gene	0.60
ferroptosis	participates_in	pathway	0.60
PNN	expressed_in	gene	0.60
PV	expressed_in	gene	0.60
Rb	regulates	protein	0.60
App	regulates	protein	0.60
ARNT2	expressed_in	gene	0.60
autism spectrum disorder	interacts_with	disease	0.60
NEUROINFLAMMATION	activates	gene	0.60
JNK1	activates	gene	0.60
INFLAMMATION	activates	gene	0.60
GAIN	activates	gene	0.60
PTP1B	associated_with	gene	0.60
JNK	activates	gene	0.60

Incoming (34)

Source	Relation	Type	Str
AMPK	phosphorylates	protein	0.90
AMPK	activates	gene	0.64
ROS	inhibits	gene	0.60
DLK1	activates	gene	0.60
FERROPTOSIS	activates	gene	0.60
ARNT2	inhibits	gene	0.60
AND	regulates	gene	0.60
SHANK3	interacts_with	gene	0.60
KCNH7	interacts_with	gene	0.60
AND	interacts_with	gene	0.60
NEURON	regulates	gene	0.60
STROKE	activates	gene	0.60
KRAS	inhibits	gene	0.60
CANCER	associated_with	gene	0.60
ERK	expressed_in	gene	0.60
CD36	expressed_in	gene	0.60
FAS	expressed_in	gene	0.60
SCD1	expressed_in	gene	0.60
SPR	therapeutic_target	gene	0.60
LDL	therapeutic_target	gene	0.60
AND	inhibits	gene	0.60
CANCER	inhibits	gene	0.60
NEUROINFLAMMATION	activates	gene	0.60
INFLAMMATION	activates	gene	0.60
PTP1B	associated_with	gene	0.60
OXIDATIVE STRESS	activates	gene	0.60
JNK1	activates	gene	0.60
ATP	activates	gene	0.60
GAIN	activates	gene	0.60
AND	activates	gene	0.60
JNK	activates	gene	0.60
DNA	associated_with	gene	0.60
SST	regulates	gene	0.60
metformin	targets	drug	0.60

Targeting Hypotheses (23)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Chromatin Accessibility Restoration via BRD4 Modulation	0.768	neurodegeneration	Epigenetic reprogramming in aging neuron
APOE4 astrocytes exhibit impaired cholesterol efflux via ABC	0.760	neuroscience	APOE4-driven lipid metabolism dysregulat
SGMS1-Driven Sphingomyelin Accumulation Impairs BACE1 Lysoso	0.734	neurodegeneration	What molecular mechanisms link elevated
APOE4-driven lysosome-to-ER cholesterol transport failure re	0.690	molecular biology	Does APOE4's reduced lipid-binding direc
Loss of AQP4 Polarization Impairs Glymphatic Perivascular In	0.690	neurodegeneration	What are the specific molecular mechanis

hnRNPA2B1-Mediated Structural Remodeling Controls lncRNA-002	0.684	molecular neurobiology	View
Hippocampal-Cortical Transcriptomic Divergence Reveals Accel	0.680	Alzheimer disease	Allen Mouse Brain Aging Atlas: cross-age
Bacterial Tyramine–Induced DOPAL Accumulation in Enteric Neu	0.680	neurodegeneration	What are the mechanisms by which gut mic
TREM2 R47H Metabolic Lock-in at Cholesterol Ester Accumulati	0.672	neuroimmunology	What is the temporal sequence of TREM2 s
TREM2 R47H variant synergizes with APOE4 to collapse microgl	0.670	neuroscience	APOE4-driven lipid metabolism dysregulat
mTORC1 displacement from lysosomal surface enables calcineur	0.650	neurodegeneration	What determines the specificity of calci
Designer TRAK1-KIF5 fusion proteins accelerate therapeutic m	0.621	neurodegeneration	Mitochondrial transfer between astrocyte
Age-Accelerated miR-155 Upregulation Primes Nigral Microglia	0.610	neuroinflammation	How do regional, age, and sex-dependent
APOE4 Creates Accelerated, Compressed Reversibility Window	0.584	neurodegeneration	What is the optimal therapeutic window f
HBOT (2.0 ATA, 60 min) activates TFEB-mediated autophagy-lys	0.560	neurodegeneration	What are the optimal oxygen pressure, du
TRIM21-Mediated Ubiquitination Creates Peripheral Epitope Gr	0.548	neurodegeneration	What determines the spatial organization
NLRP3 Inflammasome Chromatin Priming Through H3K27ac Accumul	0.530	developmental neurobiology	Do perinatal immune challenges create pe
Metabolic Accumulation (Ammonia/Manganese) Triggers IBA1 Dow	0.517	neuroinflammation	What causes IBA1 low/negative microglia
TREM2-Mediated Microglial Metabolic Reprogramming Accelerate	0.494	neuroscience	Circuit-level neural dynamics in neurode
Lysosomal Accumulation-Induced V-ATPase Inhibition (Osmotic	0.470	neurodegeneration	Why do structurally diverse sugars (treh
Casein Kinase 2 (CK2)-Mediated Hyperphosphorylation of G3BP1	0.440	neurodegeneration	How do pathological stress granules in n
APOE4 alters the accessible-cholesterol threshold sensed by	0.420	molecular biology	Does APOE4's reduced lipid-binding direc
Hippocampal mitochondrial dysfunction accelerates with age a	0.374	Alzheimer's disease	Allen Mouse Brain Aging Atlas: cross-age

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Experiments (9)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
Unilateral ureteral obstruction model for hyperoside treatment	validation	chronic kidney disease	0.900	0.00	unilateral ureteral obstructio	proposed	N/A
Folic acid-induced nephropathy model for hyperoside renoprotection	validation	chronic kidney disease	0.900	0.00	folic acid-induced nephropathy	proposed	N/A
Hyperoside-ACAT1 direct binding interaction studies	exploratory	chronic kidney disease	0.850	0.00	in vitro protein-ligand bindin	proposed	N/A
L-carnitine rescue experiments in metabolic pathway	exploratory	chronic kidney disease	0.800	0.00	ACAT1 knockdown with L-carniti	proposed	N/A
Acat1 knockdown functional validation experiment	exploratory	chronic kidney disease	0.800	0.00	Acat1 knockdown cells/tissues	proposed	N/A
Cognitive Reserve Mechanisms in Alzheimer's Disease — Molecular Basis	clinical	Alzheimer's Disease	0.400	0.50	human	proposed	$6,550,000
Epigenetic Dysregulation in Huntington's Disease — Therapeutic Targeti	validation	Neurodegeneration	0.400	0.50	human	proposed	$3,000,000
Epigenetic Dysregulation Validation in Parkinson's Disease	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$7,500,000
Epigenetic Regulation Dysfunction in Alzheimer's and Parkinson's Disea	clinical	Alzheimer's Disease	0.400	0.50	human	proposed	$7,500,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year
Sertad4 Regulates Pathological Cardiac Remodeling. [PMID:41889836]	Francois A, Bermeo-Blanco O, Nguyen BT,	bioRxiv : the preprint server	2026
Hsp70-Targeting Chimeras Enable Dual Proteasomal and Lysosomal Degradation of In [PMID:41874277]	Wang Z, Li P, Yin F, Zhang H, Wang S, Te	Journal of medicinal chemistry	2026
Cartilage targeting hydrogel nanoplatform degrades BRD4 to alleviate osteoarthri [PMID:41904167]	Zhao Q, Xu T, Du Z, Lu X, Zhang Y, Peng	Nature communications	2026
Molecular insights for the tumor suppressor role of SPOP in prostate cancer. [PMID:41707797]	Yan P, Xue X, Hou T, Wang J, Jiang W et	Biochim Biophys Acta Rev Cance	2026
Nutrient-driven histone acetylation underlies energy storage and mobilization. [PMID:41786244]	Chen L, Zhu L, Xiao H, Wang X, Xia F et	Mol Metab	2026
Alkyne Two-Phase Strategy: Rapid Generation of TK-285-Derived PROTACs as BRD4 De [PMID:41852276]	Yamakoshi H, Watanabe R, Segawa R, Ishih	Journal of medicinal chemistry	2026
The epigenetic and epitranscriptomic regulation of Brd4-Mettl3 axis on STING med [PMID:41917296]	Zhao J, Luo X, Wang Z, Luo W, Wu S, Ma X	Inflammation research : offici	2026
Punicalagin with anti-inflammatory activities affects Brd-4 mediated chromatin r [PMID:41807492]	Li H, Li Q, Wan T, Wang Y, Zhang S	Scientific reports	2026
Targeting BRD4-A Promising Therapeutic Option for Glioblastoma? [PMID:41828493]	Lindner M, Lisińska D, Kędzierzyńska A,	International journal of molec	2026
High-intensity interval training alleviates COPD-induced gastrocnemius muscle dy [PMID:41865095]	Zhu C, Peng W, Yang L, Zhang W	Journal of muscle research and	2026
A photothermal immune hydrogel dressing for enhanced post-melanoma resection tre [PMID:41877232]	Tan D, Zhu W, Liu S, Liao F, Xu X, Luo J	Journal of nanobiotechnology	2026
Recovery of FAM134A-mediated ER-phagy through BRD4 inhibition alleviates ethanol [PMID:40959274]	["Lim J", "Chae C", "Yoon J", "Cho J", "	International journal of biolo	2025
A human Tau expressing zebrafish model of progressive supranuclear palsy identif [PMID:39294122]	["Bai Q", "Shao E", "Ma D", "Jiao B", "S	Nature communications	2024
Targeted Protein O-GlcNAcylation Using Bifunctional Small Molecules. [PMID:38561350]	["Ma B", "Khan K", "Xu T", "Xeque Amada	Journal of the American Chemic	2024
Chem-CRISPR/dCas9FCPF: a platform for chemically induced epigenome editing. [PMID:39315698]	["Altinbay M", "Wang J", "Chen J", "Sch\	Nucleic acids research	2024
Epigenetic modulation through BET bromodomain inhibitors as a novel therapeutic [PMID:38643236]	["Rosenthal Z", "Fass D", "Payne N", "Sh	Scientific reports	2024
A novel PROTAC molecule dBET1 alleviates pathogenesis of experimental autoimmune [PMID:39002520]	["Song Z", "Li J", "He Y", "Wang X", "Ti	International immunopharmacolo	2024
Bromodomain-containing protein 4 (BRD4): a key player in inflammatory bowel dise [PMID:36710583]	["Ma Z", "Bolinger A", "Zhou J", "Tian B	Expert opinion on therapeutic	2023
Genetic and epigenetic regulators of retinal Müller glial cell reprogramming. [PMID:37846362]	["Xiao X", "Liao Z", "Zou J"]	Advances in ophthalmology prac	2023
Bromodomain and Extra-Terminal Proteins in Brain Physiology and Pathology: BET-i [PMID:36979729]	["Martella N", "Pensabene D", "Varone M"	Biomedicines	2023

Debates (0)

Multi-agent debates referencing this entity

No debates reference this entity

ACC